Enteral and Parenteral Electrolyte Therapeutics

Abstract

Get full access to this article

View all access options for this article.

References

1. Steuer RR , Harris DH , Conis JM. A new optical technique for monitoring hematocrit and circulating blood volume: Its application in renal dialysis. Dial Transplant 22:200–265, 1993

2. Phang PT , Aeberhardt LE. Effect of nutritional support on routine nutrition assessment parameters and body composition in intensive care unit patients. Can J Surg 39:212–219, 1996

3. Humphreys MH.

Salt intake and body fluid volumes: Have we learned all there is to know?

Am J Kidney Dis 37:648–652, 2001

4. Below PR , Mora-Rodriguez R , Gonzalez-Alonso J , et al. Fluid and carbohydrate ingestion independently improve performance during 1 h of intense exercise. Med Sci Sports Exerc 27:200–210, 1995

5. Walsh RM , Noakes TD , Hawley JA , et al. Impaired high-intensity cycling performance time at low levels of dehydration. Int J Sports Med 15:392–398, 1994

6. Shapiro Y , Moran D , Epstein Y. Validation and adjustment of the mathematical prediction model for human sweat rate responses to outdoor environmental conditions. Ergonomics 38:981–986, 1995

7. Alsous F , Khamiees M , DcGirolamo A , et al. Negative fluid balance predicts survival in patients with septic shock: A retrospective pilot study. Chest 117:1749–1754, 2000

8. Jaeger JQ , Mehta RL. Assessment of dry weight in hemodialysis: An overview. J Am Soc Nephrol 10:392–403, 1999

9. Weil J , Lang RE , Suttmann H , et al. Concomitant increase in plasma atrial natriuretic peptide and cyclic GMP in man during volume loading. Klin Wochenschr 63:1265–1268, 1985

10.

10. Nunez C . Estimates of body water compartments with use of bioelectrical impedance analysis. Am J Clin Nutr 73:845–846, 2001

11.

11. Miller M. Syndromes of excess antidiuretic hormone release. Crit Care Clin 17:11–23, 2001

12.

12. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 10:287–294, 2000

13.

13. Polderman KH , Schreuder WO , Strack van Schijndel RJ , et al. Hypernatremia in the intensive care unit: An indicator of quality of care? Crit Care Med 27:1105–1108, 1999

14.

14. Torpy DJ , Stratakis CA , Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm 57:177–216, 1999

15.

15. Perez GO , Oster JR , Vaamonde CA. Serum potassium concentration in acidemic states. Nephron 27:233–243, 1981

16.

16. Yelamanchi VP , Molnar J , Ranade V , et al. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther 8:117–122, 2001

17.

17. Ruml LA , Sakhaee K , Peterson R , et al. The effect of calcium citrate on bone density in the early and mid-postmenopausal period: A randomized placebo-controlled study. Am J Ther 6:303–311, 1999

18.

18. Zaloga GP , Willey S , Malcolm D , et al. Hypercalcemia attenuates blood pressure response to epinephrine. J Pharmacol Exp Ther 247:949–952, 1988

19.

19. Neer RM , Arnaud CD , Zanchetta JR , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441, 2001

20.

20. Zaloga GP , Chernow B , Smallridge RC , et al. A longitudinal evaluation of thyroid function in critically ill surgical patients. Ann Surg 201:456–464, 1985

21.

21. Kelly GS. Peripheral metabolism of thyroid hormones: A review. Altern Med Rev 5:306–333, 2000

22.

22. Forceville X , Vitoux D , Gauzit R , et al. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med 26:1536–1544, 1998

23.

23. Zaloga GP , Eil C , O'Brian JT. Reversible hypocalciuric hypercalcemia associated with hypothyroidism. Am J Med 77:1101–1104, 1984

24.

24. McCarron DA , Pingree PA , Rubin RJ , et al. Enhanced parathyroid function in essential hypertension: A homeostatic response to a urinary calcium leak. Hypertension 2:162–168, 1980

25.

25. McCarron DA , Morris CD , Cole C. Dietary calcium in human hypertension. Science 217:267–269, 1982

26.

26. Henry HJ , McCarron DA , Morris CD , et al. Increasing calcium intake lowers blood pressure: The literature reviewed. J Am Diet Assoc 85:182–185, 1985

27.

27. McCarron DA , Reusser ME. Finding consensus in the dietary calcium-blood pressure debate. J Am Coll Nutr 18(5 Suppl):398S–405S, 1999

28.

28. Miller GD , DiRienzo DD , Reusser ME , et al. Benefits of dairy product consumption on blood pressure in humans: A summary of the biomedical literaturexy0J Am Coll Nutr 19(2 Suppl);147S–164S, 2000

29.

29. McCarron DA , Morris CD. Metabolic considerations and cellular mechanism related to calcium's antihypertensive effects. Fed Proc 45:2734–2738, 1986

30.

30. Pietschmann P , Woloszczuk W , Pietschmann H. Increased serum osteocalcin levels in elderly females with vitamin D deficiency. Exp Clin Endocrinol 95:275–278, 1990

31.

31. Zivin JR , Gooley T , Zager RA , et al. Hypocalcemia: A pervasive metabolic abnormality in the critically ill. Am J Kidney Dis 37:689–698, 2001

32.

32. Zaloga GP , Willey S , Tomasic P , et al. Free fatty acids alter calcium binding: A cause for misinterpretation of serum calcium values and hypocalcemia in critical illness. J Clin Endocrinol Metab 64:1010–1014, 1987

33.

33. Zaloga GP , Youngs E , Teres D. Propofol-containing sedatives increase levels of parathyroid hormone. Intensive Care Med 26(Suppl 4):S405–S412, 2000

34.

34. Kohlmeier M , Saupe J , Shearer MJ , et al. Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int 51:1218–1221, 1997

35.

35. Camilo ME , Jatoi A , O'Brien M , et al. Bioavailability of phylloquinone from an intravenous lipid emulsion. Am J Clin Nutr 67:716–721, 1998

36.

36. Lennon C , Davidson KW , Sadowski JA , et al. The vitamin K content of intravenous lipid emulsions. JPEN 17:142–144, 1993

37.

37. Nuoranne P. On the reliability of the magnesium serum value as an indicator of body magnesium status. Nord Vet Med 30:71–73, 1978

38.

38. Sacks GS , Brown RO , Dickerson RN , et al. Mononuclear blood cell magnesium content and serum magnesium concentration in critically ill hypomagnesemic patients after replacement therapy. Nutrition 13:303–308, 1997

39.

39. Mocci F , Canalis P , Tomasi PA , et al. The effect of noise on serum and urinary magnesium and catecholamines in humans. Occup Med (Oxf) 51:56–61, 2001

40.

40. Agus MS , Agus ZS. Cardiovascular actions of magnesium. Crit Care Clin 17:175–186, 2001

41.

41. Thomas SC , Sarno A , Anasti J. Magnesium sulfate tocolysis prolongs QT interval. Obstet Gynecol 7(4 Suppl 1):S47, 2001

42.

42. Yudd M , Llach F. Current medical management of secondary? hyperparathyroidism. Am J Med Sci 320:100–106, 2000

43.

43. Lidor C , Schwartz I , Freund U , et al. Successful high-dose calcium treatment of aluminum-induced metabolic bone disease in long-term home parenteral nutrition. JPEN 15:202–206, 1991

44.

44. Hurley DL , McMahon MM. Long-term parenteral nutrition and metabolic bone disease. Endocrinol Metab Clin North Am 19:113–131, 1990

45.

45. Wood RJ , Sitrin MD , Cusson GJ , et al. Reduction of TPN-induced urinary calcium loss by increasing the phosphorus in the TPN prescription. JPEN 10:188–190, 1986

46.

46. Wood RJ , Bengoa JM , Sitrin MD , et al. Calciuretic effect of cyclic versus continuous TPN. Am J Clin Nutr 41:614–619, 1985

47.

47. Malluehe HH , Monier-Faugere MC. Hyperphosphatemia: Pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol 54:309–311, 2001

48.

48. Marik PE , Bedigian MK. Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study. Arch Surg 131:1043–1047, 1996

49.

49. Hayek ME , Eisenberg PG. Severe hypophosphatemia following the institution of enteral feedings. Arch Surg 124:1325–1328, 1989

50.

50. Perreault MM , Ostrop NJ , Tierney MG. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother 31:683–688, 1997

51.

51. Zazzo JF , Troche G , Ruel P , et al. High incidence of hypophosphatemia in surgical intensive care patients: Efficacy of phosphorus therapy on myocardial function. Intensive Care Med. 21:826–831, 1995

52.

52. Clark CL , Sacks GS , Dickerson RN , et al. Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: Results from a prospective clinical trial. Crit Care Med.x2 23:1504–1511, 1995

53.

53. Rosen GH , Boullata JI , O'Rangers EA , et al. Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 23:1204–1210, 1995

54.

54. Kingston M , Al-Siba'i MB. Treatment of severe hypophosphatemia. Crit Care Med 13:16–18, 1985

55.

55. Vannatta JB , Andress DL , Whang R , et al. High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia. South Med J 76:1424–1426, 1983

56.

56. Vannatta JB , Whang R , Papper S. Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient. Arch Intern Med 141:885–887, 1981